---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056948"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:57:22.720115+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics Q1 2024: rev $1.4M, net loss $6.5M; new Genentech OpRegen deal

## Summary
- Revenue of $1.4M, down from $2.4M YoY; net loss attributable $6.5M ($0.04/sh) vs $4.4M ($0.03/sh).
- Cash $43.6M; expected to fund operations into Q3 2025.
- New services agreement with Genentech to support OpRegen clinical and manufacturing activities.
- OpRegen Phase 1/2a long-term data: mean BCVA gain of 5.5 letters at 24 months in Cohort 4 patients.
- OPC1 clinical study start-up underway; received CIRM grant for 2nd Annual SCI Investor Symposium.

## SEC filing metadata
- accession: 0000950170-24-056948
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017024056948/0000950170-24-056948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017024056948/lctx-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056948
- JSON: https://secwatch.observer/filing/0000950170-24-056948.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056948.txt

## Key facts
- Earnings Releases
  Lineage Cell Therapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $1.4 million.
  - Period: the quarter ended March 31, 2024
  - Revenue: $1.4 million
  - Result: reported results
  source text: Total revenues for the three months ended March 31, 2024 were approximately $1.4 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000095017024056948/0000950170-24-056948-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.